Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL

Prior treatment

• Previously received systemic or local treatments including chemotherapy;
• Previously underwent hematopoietic stem cell transplantation;
• Other concurrent and uncontrolled medical conditions that the researcher considers will affect the patient's participation in the study;

Other illness

• Had uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, severe infectious diseases, etc.;
• Patients with a history of allergic reactions to any drugs in this research protocol;
• Psychiatric patients or other patients known or suspected to be unable to fully comply with the study protocol;
• HIV-infected individuals.

Lab values

• Left ventricular ejection fraction ≤ 50%;
• Laboratory test values at screening (unless caused by leukemia): ALT or AST higher than twice the upper limit of normal, AKP and bilirubin higher than 1.5 times the upper limit of normal, creatinine level higher than 1.5 times the upper limit of normal;

Other

• Classified as other types of leukemia according to the WHO 2016 classification;
• Had other tumors in addition to leukemia;
• Pregnant or lactating women;

• The subjects were diagnosed with acute T-lymphocytic leukemia (according to the 2016 WHO classification) based on their bone marrow pathology and hematology, and sufficient bone marrow samples were available for PCR analysis;
• The subjects must have never received anti-leukemia treatment before;
• Age ≥ 18 years old, gender not restricted;
• The subjects' Eastern Cooperative Oncology Group (ECOG) performance status score is 0-2;
• The subjects or their legal representatives must provide written informed consent before undergoing the special examinations or procedures of the study.